Zacks: Brokerages Expect Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Post Earnings of -$0.56 Per Share

Wall Street analysts expect that Seres Therapeutics, Inc. (NASDAQ:MCRBGet Rating) will report ($0.56) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Seres Therapeutics’ earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.61). Seres Therapeutics reported earnings per share of ($0.39) in the same quarter last year, which suggests a negative year-over-year growth rate of 43.6%. The company is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Seres Therapeutics will report full year earnings of ($2.05) per share for the current fiscal year, with EPS estimates ranging from ($2.59) to ($1.47). For the next year, analysts forecast that the firm will report earnings of ($1.16) per share, with EPS estimates ranging from ($2.86) to $0.29. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). The firm had revenue of $7.22 million during the quarter, compared to analyst estimates of $19.48 million. Seres Therapeutics had a negative net margin of 45.25% and a negative return on equity of 47.52%. During the same quarter in the prior year, the business earned ($0.18) EPS.

A number of analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Seres Therapeutics in a research note on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $20.83.

Shares of NASDAQ MCRB traded down $0.44 during mid-day trading on Monday, reaching $5.64. 951,669 shares of the company were exchanged, compared to its average volume of 788,943. The company’s 50-day simple moving average is $7.34 and its 200-day simple moving average is $7.75. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $518.96 million, a P/E ratio of -7.52 and a beta of 3.36. Seres Therapeutics has a twelve month low of $5.41 and a twelve month high of $25.06.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its stake in shares of Seres Therapeutics by 338.9% during the 4th quarter. Millennium Management LLC now owns 1,264,486 shares of the biotechnology company’s stock worth $10,533,000 after purchasing an additional 976,368 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Seres Therapeutics by 527.8% during the 3rd quarter. Two Sigma Investments LP now owns 999,416 shares of the biotechnology company’s stock worth $6,956,000 after acquiring an additional 840,214 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in Seres Therapeutics during the third quarter worth approximately $5,633,000. Renaissance Technologies LLC acquired a new position in shares of Seres Therapeutics in the fourth quarter valued at approximately $6,218,000. Finally, Goldman Sachs Group Inc. boosted its position in Seres Therapeutics by 116.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,238,450 shares of the biotechnology company’s stock worth $10,316,000 after purchasing an additional 666,935 shares in the last quarter. Institutional investors own 80.53% of the company’s stock.

About Seres Therapeutics (Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Featured Articles

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.